

# Tobias Aw Holderried

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3580441/publications.pdf>

Version: 2024-02-01

42  
papers

2,296  
citations

430874

18  
h-index

377865

34  
g-index

42  
all docs

42  
docs citations

42  
times ranked

5046  
citing authors

#	ARTICLE	IF	CITATIONS
1	Preliminary Report for the Development of a Multiparameter Protocol for the Identification of Sinusoidal Obstruction Syndrome including Abdominal Ultrasound before and after Allogeneic Stem Cell Transplantation. Applied Sciences (Switzerland), 2022, 12, 829.	2.5	1
2	RefraktÃres/rezidiertes Multiples Myelom: CAR-T-Zell-Therapie zeigt betrÃchtliche Wirksamkeit. Karger Compass Onkologie, 2021, 8, 130-131.	0.0	0
3	Prevalence, therapy and tumour response in patients with rheumatic immune-related adverse events following immune checkpoint inhibitor therapy: a single-centre analysis. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2110069.	2.7	13
4	Helios-expressing CD8<sup>+</sup> T cells are decreased in patients with systemic lupus erythematosus. Lupus, 2021, 30, 1022-1024.	1.6	4
5	Fecal microbiota transfer for refractory intestinal graftâ€versusâ€host disease â€” Experience from two German tertiary centers. European Journal of Haematology, 2021, 107, 229-245.	2.2	20
6	Selective ABO immunoadsorption in hematopoietic stem cell transplantation with major ABO incompatibility. European Journal of Haematology, 2021, 107, 324-332.	2.2	3
7	ROCKing Chronic Graft-Versus-Host Disease. Journal of Clinical Oncology, 2021, 39, JCO.21.01081.	1.6	1
8	Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia. Blood Cancer Journal, 2021, 11, 164.	6.2	29
9	959â€...Safety and anti-tumor activity of TCR-engineered autologous, PRAME-directed T cells across multiple advanced solid cancers at low doses â€” clinical update on the ACTEngineÂ® IMA203 trial. , 2021, 9, A1009-A1009.		15
10	Addition of Isatuximab to Lenalidomide, Bortezomib and Dexamethasone As Induction Therapy for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma Patients: The Phase III GMMG-HD7 Trial. Blood, 2021, 138, 463-463.	1.4	19
11	Treatment with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine in AML Patients Shows MRD Conversion and Improved Survival. Blood, 2021, 138, 1274-1274.	1.4	2
12	Higher number of multidisciplinary tumor board meetings per case leads to improved clinical outcome. BMC Cancer, 2020, 20, 355.	2.6	33
13	Treatment Response Monitoring in Patients with Advanced Malignancies Using Cell-Free SHOX2 and SEPT9 DNA Methylation in Blood. Journal of Molecular Diagnostics, 2020, 22, 920-933.	2.8	15
14	NK Cells Regulate CD8+ T Cell Mediated Autoimmunity. Frontiers in Cellular and Infection Microbiology, 2020, 10, 36.	3.9	20
15	Prognostic and predictive value of PD-L2 DNA methylation and mRNA expression in melanoma. Clinical Epigenetics, 2020, 12, 94.	4.1	26
16	FRI0548â€...PREVALENCE AND THERAPY OF RHEUMATOLOGICAL ADVERSE EVENTS DUE TO IMMUNE CHECKPOINT INHIBITOR THERAPY. Annals of the Rheumatic Diseases, 2020, 79, 875.1-876.	0.9	2
17	The Role of Immune Checkpoints after Cellular Therapy. International Journal of Molecular Sciences, 2020, 21, 3650.	4.1	7
18	Conversion from MRD Positive to Negative Status in AML Patients in CR1 after Treatment with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine. Blood, 2020, 136, 13-14.	1.4	2

#	ARTICLE	IF	CITATIONS
19	The role of checkpoint blockade after allogeneic stem cell transplantation in diseases other than Hodgkin's Lymphoma. Bone Marrow Transplantation, 2019, 54, 1662-1667.	2.4	22
20	Molecular and immune correlates of TIM-3 (HAVCR2) and galectin 9 (LGALS9) mRNA expression and DNA methylation in melanoma. Clinical Epigenetics, 2019, 11, 161.	4.1	49
21	On-demand erythrocyte disposal and iron recycling requires transient macrophages in the liver. Nature Medicine, 2016, 22, 945-951.	30.7	333
22	Long-term survival correlates with immunological responses in renal cell carcinoma patients treated with mRNA-based immunotherapy. OncoImmunology, 2016, 5, e1108511.	4.6	41
23	Human CD8+ Treg after Allogeneic Stem-Cell Transplantation. Blood, 2016, 128, 2243-2243.	1.4	0
24	Stable inhibitory activity of regulatory T cells requires the transcription factor Helios. Science, 2015, 350, 334-339.	12.6	323
25	Ly-6C <sup>high</sup> Monocytes Depend on Nr4a1 to Balance Both Inflammatory and Reparative Phases in the Infarcted Myocardium. Circulation Research, 2014, 114, 1611-1622.	4.5	427
26	Disruption of CD8+ Treg Activity Results in Expansion of T Follicular Helper Cells and Enhanced Antitumor Immunity. Cancer Immunology Research, 2014, 2, 207-216.	3.4	38
27	Innate Response Activator B Cells Aggravate Atherosclerosis by Stimulating T Helper-1 Adaptive Immunity. Circulation, 2014, 129, 1677-1687.	1.6	107
28	Genetic disruption of CD8 <sup>+</sup> Treg activity enhances the immune response to viral infection. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 21089-21094.	7.1	41
29	CD8+ Treg - From Mouse To Man. Blood, 2013, 122, 3474-3474.	1.4	3
30	Releasing CD8+ Treg Mediated Suppression Enhances Anti-Viral Immune Response. Blood, 2013, 122, 2280-2280.	1.4	0
31	Immunotherapy With RNA Vaccination Coding For TAA In Renal Cell Carcinoma: Update On Immunological Responses and Correlation With Survival. Blood, 2013, 122, 1040-1040.	1.4	0
32	Immunomodulatory effects of anti-angiogenic drugs. Leukemia, 2011, 25, 899-905.	7.2	60
33	Intradermal Vaccinations With RNA Coding for TAA Generate CD8+ and CD4+ Immune Responses and Induce Clinical Benefit in Vaccinated Patients. Molecular Therapy, 2011, 19, 990-999.	8.2	199
34	1/4-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 6250-6255.	7.1	112
35	Post-transcriptional regulation of adapter molecules by IL-10 inhibits TLR-mediated activation of antigen-presenting cells. Leukemia, 2009, 23, 535-544.	7.2	34
36	Characterization of BAX inhibitor-1 as a novel leukemia-associated antigen. Leukemia, 2009, 23, 1818-1824.	7.2	10

#	ARTICLE	IF	CITATIONS
37	Immunotherapy in renal cell carcinoma. <i>Immunotherapy</i> , 2009, 1, 97-107.	2.0	5
38	A Mouse Model for Immunotherapeutic Reversal of Leukemia-Induced T Cell Dysfunction. <i>Blood</i> , 2008, 112, 30-30.	1.4	0
39	Transfection of Dendritic Cells with in Vitro-Transcribed CMV RNA Induces Polyclonal CD8 <sup>+</sup> - and CD4 <sup>+</sup> -Mediated CMV-Specific T Cell Responses. <i>Molecular Therapy</i> , 2006, 13, 280-288.	8.2	21
40	Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. <i>Journal of Clinical Investigation</i> , 2005, 115, 1797-1805.	8.2	259
41	Gene Expression Profiling Identifies Similar CD4 <sup>+</sup> and CD8 <sup>+</sup> T Cell Defects in TCL1 Transgenic Mice after Development of CLL to Those Observed in Patients with CLL. <i>Blood</i> , 2004, 104, 180-180.	1.4	0
42	Cell Contact with CLL Cells Induces Defects in T Cell Differentiation and Effector Pathways: Impact of Silencing Specific Cytokine Production. <i>Blood</i> , 2004, 104, 955-955.	1.4	0